CAR-T Cell Therapy in China

Chimeric antigen receptor T-cell therapy at Beijing's leading haematology centres — with a written, itemised estimate before you commit to anything.

Why patients travel to China for CAR-T therapy

China runs one of the world's densest CAR-T research programmes. As of 2026 the NMPA has approved seven CAR-T products — more than any other country — and China became the first to approve a CAR-T therapy for a solid tumour. At leading centres the time from cell collection to infusion can be as short as 24 to 36 hours.

Hospital fees are paid by you directly to the hospital. We charge a separate fee for coordinating your case, confirmed in writing before you decide to travel — never a percentage of your medical bill.

HospitalsExpertsHow It WorksContact

What CAR-T therapy costs

Treatment Beijing United States (typical)
CAR-T with an approved product, all-in: cell manufacturing, infusion, hospital stay and management of side effects USD 150,000–250,000 USD 400,000–700,000
Clinical trial pathway, if eligible — hospital costs only, cell product provided at no charge USD 15,000–60,000 —
Twelve months of follow-up and monitoring after you return home USD 3,000–8,000 USD 20,000–60,000

Indicative ranges for international patients, based on published product pricing and our own case experience. Cell therapy pricing depends on the product, your indication and your clinical course — severe complications can extend intensive care and push the total higher. Your actual cost is confirmed in a written estimate after our panel reviews your records. Hospital fees are paid directly to the hospital; we never mark them up.

The clinical trial pathway depends on whether an open trial matches your diagnosis and on the treating centre's own assessment. Eligibility is never guaranteed and is not something we can arrange on request.

What your coordination fee covers

Pathways we coordinate

Approved commercial CAR-T

NMPA-approved CD19- and BCMA-directed products for relapsed or refractory lymphoma, leukaemia and multiple myeloma, delivered at centres with dedicated CAR-T teams.

Clinical trial enrolment

China runs more CAR-T trials than any other country. Eligibility is decided by the treating centre, not by us, and enrolment can never be guaranteed.

Complication management

Cytokine release syndrome and neurotoxicity need experienced teams with tocilizumab and intensive care on standby — we only work with centres that have both.

CAR-T therapy in China — common questions

What international patients ask before sending their records.

Who is eligible for CAR-T therapy?
CAR-T is approved for specific blood cancers — certain lymphomas, leukaemias and multiple myeloma — usually after other treatments have stopped working. Eligibility is decided by the treating haematologist after reviewing your diagnosis, previous therapies and current disease status. It is a clinical decision, and we do not make it.
How long do I need to stay in China?
Plan for six to ten weeks. Cell collection and pre-treatment take about a week, the product is manufactured within two to four weeks — as little as 24 to 36 hours at some centres — and monitoring after infusion usually needs two to four more weeks in hospital or nearby.
What are the main risks?
The two serious risks are cytokine release syndrome (high fever, falling blood pressure) and neurological toxicity. Both are manageable, but they require a centre with a dedicated CAR-T team, tocilizumab on hand and intensive care backup. We only work with hospitals that have all three.
Can I continue treatment after I go home?
You leave with your full records and imaging in your own language. We arrange telemedicine follow-up with your treating team and plan the handover to your oncologist at home before you fly back.

Send us your records for a free review

A case manager replies within 24 hours with a preliminary opinion, suitable centres and an indicative cost.

Contact Us Today